San Francisco, November 11, 2019 – Recardio Inc., a clinical-stage life science company focusing on regenerative therapies for cardiovascular diseases, participated and presented today at the BIO Europe in Hamburg.
The conference is held annually in different cities and is an international forum to promote business development between pharmaceutical, financial and biotechnology companies. The event is Europe’s largest partnering conference serving the global biotech industry. At this conference leading decision makers of the biotechnology, pharmaceutical and financial industry employed at emerging companies meet annually.
Recardio participated and presented its latest advancements from its drug-based regenerative therapy clinical development program and gave a future outlook on new therapies and expansion programs.
The BIO Europe has been taken place from the 11th to 13th of November 2019 in Hamburg, Germany.
More information about the clinical program is available by visiting the following link: http://recardio.eu/phase-2b/
Recardio Inc. is a clinical-stage life science company focusing on regenerative therapies for cardiovascular diseases. The company’s lead drug candidate, dutogliptin, is a DPP-IV inhibitor that has demonstrated significant effects in activating SDF-1, a protein that is critical for cardiac regeneration. In addition to its current Phase 2 clinical program, Recardio will fully develop the therapeutic platform as a regenerative medication for patients with various cardiovascular diseases including acute myocardial infarction and chronic heart failure, with the potential of improving heart function, quality of life and survival. For more information, visit: http://www.recardio.eu/